Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 24, 2025, titled "Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received tentative approval from the USFDA to market Ibrutinib tablets in three strengths (140 mg, 280 mg, and 420 mg), a generic version of Imbruvica. Ibrutinib is used to treat blood cancers including Chronic lymphocytic leukaemia (CLL), Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia. The reference brand had annual US sales of USD 2,148.9 million (IQVIA MAT May 2025), making this a large-market opportunity. The product will be manufactured at Zydus's SEZ facility in Ahmedabad. With this, the group has 420 approvals and 484 ANDA filings cumulatively since FY 2003-04.
Positive for shareholders — the approval targets a blockbuster molecule (over USD 2 billion US market), potentially expanding Zydus's US generics revenue. However, the 'tentative' status means launch may be delayed until patent or exclusivity barriers are resolved, so immediate revenue impact is not guaranteed.